|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
|
US20040142859A1
(en)
|
2002-05-02 |
2004-07-22 |
Steffan Joan S. |
Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
|
|
EP1390491B1
(en)
|
2001-05-02 |
2008-07-16 |
The Regents of the University of California |
Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
|
|
US20050227915A1
(en)
|
2001-05-02 |
2005-10-13 |
Steffan Joan S |
Methods and reagents for treating neurodegenerative diseases and motor deficit disorders
|
|
AU2002340253C1
(en)
|
2001-10-16 |
2011-03-31 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
|
CN101259120B
(zh)
|
2002-03-04 |
2012-07-04 |
Hdac默克研究有限责任公司 |
辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
|
|
US20050009030A1
(en)
|
2002-03-26 |
2005-01-13 |
Fabien Schweighoffer |
Histone deacetylase: novel molecular target of neurotoxicity
|
|
AU2003226014A1
(en)
|
2002-03-28 |
2003-10-13 |
Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
|
|
ITMI20040876A1
(it)
|
2004-04-30 |
2004-07-30 |
Univ Degli Studi Milano |
Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
|
|
US20060018921A1
(en)
|
2004-07-16 |
2006-01-26 |
Baylor College Of Medicine |
Histone deacetylase inhibitors and cognitive applications
|
|
GT200500321A
(es)
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
|
CN101056632B
(zh)
*
|
2004-11-09 |
2011-12-07 |
Irm责任有限公司 |
用作蛋白激酶抑制剂的化合物和组合物
|
|
US20060135612A1
(en)
|
2004-12-17 |
2006-06-22 |
U.S. Department Of Veterans Affairs |
Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
|
|
US8999289B2
(en)
|
2005-03-22 |
2015-04-07 |
President And Fellows Of Harvard College |
Treatment of protein degradation disorders
|
|
US20100004156A1
(en)
|
2005-07-27 |
2010-01-07 |
Shalesh Kaushal |
Small Compounds That Correct Protein Misfolding and Uses Thereof
|
|
EP1937236A2
(en)
|
2005-09-07 |
2008-07-02 |
Braincells, Inc. |
Modulation of neurogenesis by hdac inhibition
|
|
WO2007049262A1
(en)
|
2005-10-27 |
2007-05-03 |
Berand Limited |
Methods and compositions for the promotion of neuronal growth and the treatment of asociality and affective disorders
|
|
WO2007055941A2
(en)
|
2005-11-03 |
2007-05-18 |
Merck & Co., Inc. |
Histone deacetylase inhibitors with aryl-pyrazolyl motifs
|
|
US20070207950A1
(en)
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
|
GB0612273D0
(en)
|
2006-06-21 |
2006-08-02 |
Friedrich Miescher Inst For Bi |
Prevention of muscle atrophy
|
|
US8088951B2
(en)
|
2006-11-30 |
2012-01-03 |
Massachusetts Institute Of Technology |
Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
|
|
WO2008073733A1
(en)
|
2006-12-08 |
2008-06-19 |
Kalypsys, Inc. |
Salts of inhibitors of histone deacetylase for the treatment of disease
|
|
AU2007333799A1
(en)
|
2006-12-15 |
2008-06-26 |
Novartis Ag |
Heterocycle compounds and methods of use thereof
|
|
WO2008126932A2
(en)
|
2007-04-09 |
2008-10-23 |
Riken |
Epigenetical regulation of brain plasticity
|
|
AU2008269154B2
(en)
|
2007-06-27 |
2014-06-12 |
Merck Sharp & Dohme Llc |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
WO2009027349A2
(en)
|
2007-08-24 |
2009-03-05 |
Oryzon Genomics Sa |
Treatment and prevention of neurodegenerative diseases
|
|
US20090136461A1
(en)
|
2007-11-28 |
2009-05-28 |
Moon Suk Kim |
Neuronal differentiation method of adult stem cells using small molecules
|
|
AU2013203735A1
(en)
*
|
2007-12-04 |
2013-05-02 |
F. Hoffmann-La Roche Ag |
Isoxazolo-pyridine derivatives
|
|
BR112012015129A2
(pt)
*
|
2009-12-22 |
2019-09-24 |
Celgene Corp |
"composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio"
|
|
US8981084B2
(en)
|
2010-01-13 |
2015-03-17 |
Tempero Pharmaceuticals, Inc. |
Oxadiazole HDAC inhibitors
|
|
AU2011205283B2
(en)
|
2010-01-13 |
2014-07-10 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
|
WO2012018499A2
(en)
|
2010-08-05 |
2012-02-09 |
Acetylon Pharmaceuticals |
Specific regulation of cytokine levels by hdac6 inhibitors
|
|
ES2647368T3
(es)
|
2010-10-08 |
2017-12-21 |
Vib Vzw |
Inhibidores de HDAC para tratar la enfermedad de Charcot-Marie-Tooth
|
|
EP2632900A2
(en)
|
2010-10-28 |
2013-09-04 |
Merck Sharp & Dohme Corp. |
Caprolactam mglur5 receptor modulators
|
|
US10059723B2
(en)
|
2011-02-28 |
2018-08-28 |
Biomarin Pharmaceutical Inc. |
Histone deacetylase inhibitors
|
|
US8957066B2
(en)
|
2011-02-28 |
2015-02-17 |
Biomarin Pharmaceutical Inc. |
Histone deacetylase inhibitors
|
|
US9540395B2
(en)
|
2011-02-28 |
2017-01-10 |
Biomarin Pharmaceutical Inc. |
Histone deacetylase inhibitors
|
|
CA2834548C
(en)
|
2011-04-28 |
2021-06-01 |
The Broad Institute, Inc. |
Inhibitors of histone deacetylase
|
|
US20140235649A1
(en)
|
2011-05-24 |
2014-08-21 |
Lixte Biotechnology, Inc. |
Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
|
|
WO2013006408A1
(en)
|
2011-07-01 |
2013-01-10 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
|
EA201490228A1
(ru)
|
2011-07-08 |
2014-08-29 |
Новартис Аг |
Новые производные трифторметилоксадиазола и их применение для лечения заболевания
|
|
WO2013009827A1
(en)
|
2011-07-13 |
2013-01-17 |
Tempero Pharmaceuticals, Inc. |
Methods of treatment
|
|
WO2013009830A1
(en)
|
2011-07-13 |
2013-01-17 |
Tempero Pharmaceuticals, Inc. |
Methods of treatment
|
|
WO2013009810A1
(en)
|
2011-07-13 |
2013-01-17 |
Tempero Pharmaceuticals, Inc. |
Methods of treatment
|
|
EP2734500A4
(en)
|
2011-07-20 |
2015-04-08 |
Gen Hospital Corp |
SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
|
|
WO2013066838A1
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Llc |
Compounds and methods
|
|
WO2013066831A1
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Llc |
Compounds and methods
|
|
WO2013066833A1
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Llc |
Compounds and methods to inhibit histone deacetylase (hdac) enzymes
|
|
WO2013066839A2
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Llc |
Compounds and methods
|
|
WO2013066835A2
(en)
|
2011-10-31 |
2013-05-10 |
Glaxosmithkline Llc |
Compounds and methods
|
|
BR112014012815A8
(pt)
|
2011-11-28 |
2017-06-20 |
Novartis Ag |
derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
|
|
US9480673B2
(en)
|
2012-03-29 |
2016-11-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Composition and method for treating neurodegenerative disease
|
|
EP2841067A4
(en)
|
2012-04-25 |
2016-04-13 |
Univ California |
MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
|
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
|
CN104894060B
(zh)
|
2014-03-03 |
2018-11-06 |
中国科学院上海生命科学研究院 |
诱导体细胞转分化为神经干细胞的方法及其应用
|
|
JP6392888B2
(ja)
*
|
2014-03-12 |
2018-09-19 |
チョン クン ダン ファーマシューティカル コーポレーション |
ヒストン脱アセチル化酵素６阻害剤としての新規化合物およびこれを含む薬剤学的組成物
|
|
US10081624B2
(en)
|
2014-08-26 |
2018-09-25 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
JPWO2016039398A1
(ja)
|
2014-09-09 |
2017-06-15 |
国立大学法人大阪大学 |
含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
|
|
PL3292116T3
(pl)
|
2015-02-02 |
2022-02-21 |
Valo Health, Inc. |
3-arylo-4-amidobicykliczne kwasy [4,5,0]hydroksamowe jako inhibitory hdac
|
|
CN107848695A
(zh)
*
|
2015-06-30 |
2018-03-27 |
Wm.雷格利 Jr.公司 |
用于糖果产品的包装和用于形成该包装的方法
|
|
JPWO2017014170A1
(ja)
*
|
2015-07-17 |
2018-04-26 |
武田薬品工業株式会社 |
複素環化合物
|
|
AU2016297362B2
(en)
|
2015-07-17 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
Oxadiazole derivatives useful as HDAC inhibitors
|
|
CN108026056B
(zh)
|
2015-07-27 |
2021-08-03 |
株式会社钟根堂 |
作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物
|
|
PL3328843T3
(pl)
|
2015-07-27 |
2023-02-27 |
Chong Kun Dang Pharmaceutical Corp. |
Związki będące pochodnymi 1,3,4 oksadiazolosulfonamidów jako inhibitor deacetylazy histonowej 6, oraz kompozycja farmaceutyczna je zawierająca
|
|
RU2695227C9
(ru)
*
|
2015-07-27 |
2020-03-04 |
Чонг Кун Данг Фармасьютикал Корп. |
Производные 1,3,4-оксадиазолсульфамида в качестве ингибитора гистондеацетилазы 6 и содержащая их фармацевтическая композиция
|
|
JP6491393B2
(ja)
|
2015-08-04 |
2019-03-27 |
チョン クン ダン ファーマシューティカル コーポレーション |
ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
|
|
WO2017033946A1
(ja)
|
2015-08-25 |
2017-03-02 |
武田薬品工業株式会社 |
複素環化合物
|
|
JP6697074B2
(ja)
*
|
2015-10-12 |
2020-05-20 |
チョン クン ダン ファーマシューティカル コーポレーション |
ヒストン脱アセチル化酵素６阻害剤としてのオキサジアゾールアミン誘導体化合物及びこれを含有する薬剤学的組成物
|
|
WO2017222952A1
(en)
*
|
2016-06-23 |
2017-12-28 |
Merck Sharp & Dohme Corp. |
3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
US20180016314A1
(en)
|
2016-07-12 |
2018-01-18 |
Children's Hospital Medical Center |
Treatment of disease via transcription factor modulation
|
|
WO2018165520A1
(en)
|
2017-03-10 |
2018-09-13 |
Vps-3, Inc. |
Metalloenzyme inhibitor compounds
|
|
WO2018215597A1
(en)
|
2017-05-24 |
2018-11-29 |
Orphazyme A/S |
Heat shock protein inducers and frontotemporal disorders
|
|
CN111032651A
(zh)
|
2017-07-31 |
2020-04-17 |
武田药品工业株式会社 |
杂环化合物
|
|
US11458122B2
(en)
|
2017-08-09 |
2022-10-04 |
Children's Hospital Medical Center |
Methods for treating diseases and nerve injuries
|
|
US20200216563A1
(en)
|
2017-08-10 |
2020-07-09 |
Friedrich Miescher Institute For Biomedical Research |
Hdac6 and protein aggregation
|
|
JP6910984B2
(ja)
|
2018-03-30 |
2021-07-28 |
株式会社ホンダアクセス |
脱出ハンマー収容具
|
|
KR102316234B1
(ko)
|
2018-07-26 |
2021-10-22 |
주식회사 종근당 |
히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
|
|
JP7631193B2
(ja)
|
2018-10-22 |
2025-02-18 |
アルミス インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
US12084436B2
(en)
|
2019-01-30 |
2024-09-10 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
WO2021060567A1
(en)
*
|
2019-09-27 |
2021-04-01 |
Takeda Pharmaceutical Company Limited |
2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
|